As clinical trial activity in the Asia Pacific region continues to
boom, Novotech, the largest Australian owned contract research
organisation (CRO) has presented a checklist to help pharma firms
minimise risk when choosing a partner.
China could be the first country to conduct human stem cell trials
and presents a significant opportunity for Western companies who
are brave enough to use this risky destination as a place to pursue
this potentially lucrative sector...
China-based Natural Pharmatech has formed its first research
contract with a Japanese company, Kobayashi Pharmaceutical -
another step forward in Natural Pharmatech's plans to bring its
botanical R&D services to the global...
Discovery Partners International is offloading its unprofitable
contract drug discovery operations and merging with Infinity
Pharmaceuticals to create a new public company focused on cancer
drug discovery and development.
As China improves its resources and regulatory processes it will
soon become a hotbed of clinical drug research activity, and
position itself as one of the world's most important countries in
this field, according to a new report...
As contract research organisations (CROs) continue to search for
cost-effective countries in which to operate, the clinical trials
market is increasingly expanding into emerging economies. Central
and Eastern Europe are continuing...
Drug companies are leaning more heavily on contract research
organisations (CROs) to save costs in getting new drugs to market.
And it is paying off, with added benefits. Companies who rely on
CROs are also completing clinical trials...
UK's Pharmagene has joined forces with US company Asterand to form
a human tissue supply and research services company that will
dominate the pharma industry. The merger, which was finalised last
week, will also solidify Pharmagene's...